But results come from a curated dataset, with no in-trial comparator.
ApexOnco Front Page
Recent articles
Global data are in the same ballpark as Chinese results presented earlier this year.
Regeneron is facing two FDA decisions for its T-cell engagers.
The Avanzar study could read out shortly.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
The company reckons its immunotherapy could improve on Keytruda.
“We need all the capital we can get our hands on," the company states.
